aseptic technique comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-05-27. Numbers and descriptions here follow the published literature rather than marketing material.
After a dried peptide is dissolved, the resulting solution is treated as a distinct material with its own stability profile. Temperature, pH, ionic strength, and peptide concentration all influence how long the solution remains suitable for its intended laboratory use. Some sequences are prone to oxidation, deamidation, or aggregation. Because these processes vary widely, no single storage condition applies to every peptide. Buffer composition and light exposure can also shift degradation rates.
Aseptic technique matters when the solution will contact cells or biological reagents. Working in a clean environment, using sterile liquids and containers, and minimizing open-vial time reduce the chance of microbial contamination. Filtration through a sterile filter can remove particles and microorganisms, but some filters adsorb peptides and some peptides are retained by certain membrane materials. Compatibility between the peptide, solvent, and filter should be checked when recovery is critical.
After reconstitution, the peptide solution is less stable than the dried powder because water enables hydrolysis, oxidation, and microbial growth. Storage temperature, pH, buffer composition, and container material all affect how long the solution remains usable. Many peptides are kept at 2–8 °C for short-term work, while frozen aliquots at −20 °C or below are used for longer intervals. Repeated freeze-thaw cycles can cause aggregation or precipitation. The choice of storage condition should be based on stability data for the specific peptide.
Quality checks after reconstitution include visual inspection, pH measurement, and analytical methods such as reversed-phase high-performance liquid chromatography. These tests can detect insoluble material, degradation products, and changes in concentration. Mass spectrometry is often used to confirm molecular identity when the peptide sequence is known. Because a clear solution can still contain aggregates or modified peptide, visual clarity alone is not sufficient. Analytical results are compared with a reference standard or the pre-reconstitution certificate of analysis.
| Property | Value | Notes |
|---|---|---|
| Appearance after dissolution | Clear to slightly opalescent solution | Cloudiness or particles may indicate incomplete dissolution, aggregation, or contamination. |
| pH range for stability | Peptide-dependent | Many peptides are most stable near neutral pH, but some require acidic or slightly basic conditions. |
| Common preservative | None for many research uses | Antimicrobial preservatives can alter assays or react with peptides; use depends on application. |
| Typical container material | Borosilicate glass or low-binding plastic | Some peptides adsorb to plastic surfaces; siliconized or low-binding tubes can reduce loss. |
| Common quality check | RP-HPLC, LC-MS, UV absorbance | Identity, purity, and concentration are separate attributes; no single method measures all three. |
Peptide reconstitution is the process of dissolving a lyophilized peptide in a liquid to form a solution for later use. Lyophilization removes water under vacuum, leaving a dry powder or porous cake. Reconstitution reintroduces solvent so the peptide molecules return to a dissolved state. The solvent may be purified water, a buffer, or a mixture containing an organic co-solvent. The choice depends on the peptide sequence, its charge, and its hydrophobicity.
During reconstitution, solvent penetrates the dry cake and breaks intermolecular contacts that held the peptide in solid form. Dissolution occurs as individual peptide molecules become surrounded by solvent. Hydrophobic regions can associate with one another instead of dissolving, which may produce turbidity or aggregates. pH and ionic strength influence the charge state of ionizable groups and therefore solubility. Buffer salts can help maintain a stable pH, but they can also participate in interactions that affect the final solution.
Storage conditions for reconstituted peptides are product-specific. Cool temperatures slow many degradation pathways, but freezing can concentrate solutes and promote aggregation. Light exposure can oxidize susceptible residues such as methionine, cysteine, or tryptophan. Oxygen in headspace can contribute to oxidation, while acidic or basic pH can drive hydrolysis and deamidation. The best storage condition for a given sequence is often determined empirically because general rules do not capture all sequence-specific effects.
Quality control of reconstituted peptides combines visual inspection with instrumental analysis. A clear solution does not prove correct identity or purity, and a cloudy solution does not always indicate failure. Reverse-phase high-performance liquid chromatography can separate the peptide from related impurities, while mass spectrometry confirms molecular mass and detects modifications. pH measurement and osmolality checks provide additional information about the solution environment, and documentation of lot number, solvent, and storage history supports traceability.
Years after the conference, people ascribed a large amount of significance to it. According to Paul Berg and Maxine Singer in 1995, the conference marked the beginning of an exceptional era for both science and the public discussion of science policy. The guidelines devised by the conference enabled scientists to conduct experiments with recombinant DNA technology, which by 1995 dominated biological research. This research, in turn, increased knowledge about fundamental life processes, such as the cell cycle. Additionally, the conference, along with public debates on recombinant DNA, increased public interest in biomedical research and molecular genetics. For this reason, by 1995, genetics and its vocabulary had become a part of the daily press and television news. This, in turn, stimulated knowledgeable public discussion about some of the social, political, and environmental issues that emerged from genetic medicine and the use of genetically modified plants in agriculture. Another significant outcome of the conference was the precedent it set about how to respond to changes in scientific knowledge. According to the conference, the proper response to new scientific knowledge was to develop guidelines that governed how to regulate it.
Alpha-synuclein primary structure is usually divided in three distinct domains: Residues 1-60: An amphipathic N-terminal region dominated by four 11-residue repeats including the consensus sequence KTKEGV. This sequence has a structural alpha helix propensity similar to apolipoproteins-binding domains. It is a highly conserved terminal that interacts with acidic lipid membranes, and all the discovered point mutations of the SNCA gene are located within this terminal. Residues 61-95: A central hydrophobic region which includes the non-amyloid-β component (NAC) region, involved in protein aggregation. This domain is unique to alpha-synuclein among the synuclein family. Residues 96-140: a highly acidic and proline-rich region which has no distinct structural propensity. This domain plays an important role in the function, solubility and interaction of alpha-synuclein with other proteins.
BIA Separations was formed in 1998 by a group of scientists in Ljubljana, Slovenia to commercialize a new chromatographic resin based on monolith technology. Monolithic resin was developed independently by three different laboratories in late 1980s led by Hjertén, Švec and Tennikova. The company was one of the few Slovenian companies to receive venture capital funding at that time-Horizonte Venture Management realizing the potential of monoliths made the initial investment in the company. During that year, BIA Separations released its first commercial product marketed under the trade name of CIM (Convective Interaction Media). The new technique was named HPMC (High Performance Monolith Chromatography). During the 1999 and 2000s, the company promoted this new platform technology to the scientific and business community and registered several patents. In 2007 the company headquarters moved to Villach, Austria. In 2011 BIA Separations entered a strategic partnership with Japan Synthetic Rubber Corporation, a Japanese company producing synthetic materials. A strategic partnership agreement with Showa Denko K.K. (SDK) was signed in 2012.
Sources: en.wikipedia.org
Cabergoline was first synthesized by scientists working for the Italian drug company Farmitalia-Carlo Erba in Milan who were experimenting with semisynthetic derivatives of the ergot alkaloids, and a patent application was filed in 1980. The first publication was a scientific abstract at the Society for Neuroscience meeting in 1991. Farmitalia-Carlo Erba was acquired by Pharmacia in 1993, which in turn was acquired by Pfizer in 2003. Cabergoline was first marketed in The Netherlands as Dostinex in 1992. The drug was approved by the FDA on December 23, 1996. It went generic in late 2005 following US patent expiration. Brand names of cabergoline include Cabaser, Dostinex, Galastop (veterinary), and Kelactin (veterinary), among others. Cabergoline was studied in one person with Cushing's disease, to lower adrenocorticotropic hormone (ACTH) levels and cause regression of ACTH-producing pituitary adenomas. Substituted lysergamide Cabergoline – Isomer Design
The adipokines, or adipocytokines (Greek adipo-, fat; cytos-, cell; and -kinos, movement) are cytokines (cell signaling proteins) secreted by adipose tissue. Some contribute to an obesity-related low-grade state of inflammation or to the development of metabolic syndrome, a constellation of diseases including, but not limited to, type 2 diabetes, cardiovascular disease and atherosclerosis. The first adipokine to be discovered was leptin in 1994. Since that time, hundreds of adipokines have been discovered. Members include: Leptin Adiponectin Apelin chemerin interleukin-6 (IL-6) monocyte chemotactic protein-1 (MCP-1) plasminogen activator inhibitor-1 (PAI-1) retinol binding protein 4 (RBP4) tumor necrosis factor visfatin omentin vaspin (SERPINA12) progranulin CTRP-4 Interleukin 8 (IL-8), interleukin 10 (IL-10), interferon gamma (IFN-γ) and inducible protein 10 (IP-10 or CXCL10) have been shown to be associated with excessive body weight. Adipose tissue Hepatokines Myokines Adipokines at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
"Biosafety in Microbiological and Biomedical Laboratories", official CDC guide. "Prevention of Biological Hazards", EU-OSHA "Symbol Making", an account of the development of the symbol in 1966. "BioSeal Systems", Biosafety level 4 containment. Biohazard Remediation Compliance Overview "Example of Reclassified Biohazard to Level 4", article from The Lancet concerning the reclassification of Ebola after observation. "Biological hazards related to working alone safety", an article focusing on working alone safety when dealing with biological hazards
Sources: en.wikipedia.org
Most reconstituted peptide solutions are kept cold, often at 2–8 °C for short-term use. Longer storage may require freezing at -20 °C or below, depending on the peptide. Repeated freeze-thaw cycles can promote aggregation or degradation.
Freezing concentrates solutes and can expose peptides to ice interfaces, which may unfold or aggregate some sequences. Repeated cycles amplify these stresses. Aliquoting before freezing reduces the number of cycles a single container experiences.
Yes. Some membrane filters bind peptides, especially hydrophobic or positively charged sequences, reducing the amount recovered. Filter material and pore size should be selected with compatibility in mind. Recovery can be checked by comparing pre- and post-filtration analysis when needed.
Short-term storage is often at 2 to 8 °C, while longer storage may use frozen aliquots at −20 °C or below. Repeated freeze-thaw cycles should be avoided because they can promote aggregation.